Salarius Pharmaceuticals, Inc.
Company Snapshot: Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals, Inc. a clinical-stage biotechnology company, develops epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. Salarius Pharmaceuticals, Inc. has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.
- Oct 26 2021 Salarius Pharmaceuticals to Report Third Quarter 2021 Financial Results and Highlight Recent Company Progress
- Oct 7 2021 Salarius Pharmaceuticals and Nationwide Children’s Hospital Disclose Research Findings from Presentation at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
- Oct 5 2021 Salarius Pharmaceuticals to Present at the 2021 BioFuture Conference
- Sep 30 2021 Salarius Pharmaceuticals and Nationwide Children’s Hospital Announce Poster Presentation at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics